Profil
John Le Gall is currently Chief Medical Officer at Imugene Ltd., starting in 2026.
Formerly, Dr. Le Gall was Vice President & Head-Clinical Development at Allogene Therapeutics, Inc. from 2023 to 2026.
Education includes an MBA and a doctorate from The Trustees of Columbia University in The City of New York.
Postes actifs de John Le Gall
| Sociétés | Poste | Début |
|---|---|---|
| IMUGENE LIMITED | Directeur Technique/Scientifique/R&D | 07/10/2026 |
Anciens postes connus de John Le Gall
| Sociétés | Poste | Fin |
|---|---|---|
| ALLOGENE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2026 |
Formation de John Le Gall
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Imugene Ltd.
Imugene Ltd. BiotechnologyHealth Technology Operates as a a clinical stage immuno-oncology company | Health Technology |
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage immuno-oncology | Health Technology |
















